Literature DB >> 32369007

Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT.

Rebecca Palmer1, Munyaradzi Dimairo1, Nicholas Latimer1, Elizabeth Cross1, Marian Brady2, Pam Enderby1, Audrey Bowen3, Steven Julious1, Madeleine Harrison1, Abualbishr Alshreef1, Ellen Bradley1, Arjun Bhadhuri1, Tim Chater1, Helen Hughes1,4, Helen Witts1,5, Esther Herbert1, Cindy Cooper1.   

Abstract

BACKGROUND: People with aphasia may improve their communication with speech and language therapy many months/years after stroke. However, NHS speech and language therapy reduces in availability over time post stroke.
OBJECTIVE: This trial evaluated the clinical effectiveness and cost-effectiveness of self-managed computerised speech and language therapy to provide additional therapy.
DESIGN: A pragmatic, superiority, single-blind, parallel-group, individually randomised (stratified block randomisation, stratified by word-finding severity and site) adjunct trial.
SETTING: Twenty-one UK NHS speech and language therapy departments. PARTICIPANTS: People with post-stroke aphasia (diagnosed by a speech and language therapist) with long-standing (> 4 months) word-finding difficulties.
INTERVENTIONS: The groups were (1) usual care; (2) daily self-managed computerised word-finding therapy tailored by speech and language therapists and supported by volunteers/speech and language therapy assistants for 6 months plus usual care (computerised speech and language therapy); and (3) activity/attention control (completion of puzzles and receipt of telephone calls from a researcher for 6 months) plus usual care. MAIN OUTCOME MEASURES: Co-primary outcomes - change in ability to find treated words of personal relevance in a bespoke naming test (impairment) and change in functional communication in conversation rated on the activity scale of the Therapy Outcome Measures (activity) 6 months after randomisation. A key secondary outcome was participant-rated perception of communication and quality of life using the Communication Outcomes After Stroke questionnaire at 6 months. Outcomes were assessed by speech and language therapists using standardised procedures. Cost-effectiveness was estimated using treatment costs and an accessible EuroQol-5 Dimensions, five-level version, measuring quality-adjusted life-years.
RESULTS: A total of 818 patients were assessed for eligibility and 278 participants were randomised between October 2014 and August 2016. A total of 240 participants (86 usual care, 83 computerised speech and language therapy, 71 attention control) contributed to modified intention-to-treat analysis at 6 months. The mean improvements in word-finding were 1.1% (standard deviation 11.2%) for usual care, 16.4% (standard deviation 15.3%) for computerised speech and language therapy and 2.4% (standard deviation 8.8%) for attention control. Computerised speech and language therapy improved word-finding 16.2% more than usual care did (95% confidence interval 12.7% to 19.6%; p < 0.0001) and 14.4% more than attention control did (95% confidence interval 10.8% to 18.1%). Most of this effect was maintained at 12 months (n = 219); the mean differences in change in word-finding score were 12.7% (95% confidence interval 8.7% to 16.7%) higher in the computerised speech and language therapy group (n = 74) than in the usual-care group (n = 84) and 9.3% (95% confidence interval 4.8% to 13.7%) higher in the computerised speech and language therapy group than in the attention control group (n = 61). Computerised speech and language therapy did not show significant improvements on the Therapy Outcome Measures or Communication Outcomes After Stroke scale compared with usual care or attention control. Primary cost-effectiveness analysis estimated an incremental cost per participant of £732.73 (95% credible interval £674.23 to £798.05). The incremental quality-adjusted life-year gain was 0.017 for computerised speech and language therapy compared with usual care, but its direction was uncertain (95% credible interval -0.05 to 0.10), resulting in an incremental cost-effectiveness ratio of £42,686 per quality-adjusted life-year gained. For mild and moderate word-finding difficulty subgroups, incremental cost-effectiveness ratios were £22,371 and £28,898 per quality-adjusted life-year gained, respectively, for computerised speech and language therapy compared with usual care. LIMITATIONS: This trial excluded non-English-language speakers, the accessible EuroQol-5 Dimensions, five-level version, was not validated and the measurement of attention control fidelity was limited.
CONCLUSIONS: Computerised speech and language therapy enabled additional self-managed speech and language therapy, contributing to significant improvement in finding personally relevant words (as specifically targeted by computerised speech and language therapy) long term post stroke. Gains did not lead to improvements in conversation or quality of life. Cost-effectiveness is uncertain owing to uncertainty around the quality-adjusted life-year gain, but computerised speech and language therapy may be more cost-effective for participants with mild and moderate word-finding difficulties. Exploring ways of helping people with aphasia to use new words in functional communication contexts is a priority. TRIAL REGISTRATION: Current Controlled Trials ISRCTN68798818. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 19. See the NIHR Journals Library website for further project information. The Tavistock Trust for Aphasia provided additional support to enable people in the control groups to experience the intervention after the trial had ended.

Entities:  

Keywords:  APHASIA; COMPUTERS; HEALTH CARE COSTS; LANGUAGE THERAPY; SELF-MANAGEMENT; STROKE

Year:  2020        PMID: 32369007      PMCID: PMC7232133          DOI: 10.3310/hta24190

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  57 in total

1.  Aphasia in acute stroke and relation to outcome.

Authors:  A C Laska; A Hellblom; V Murray; T Kahan; M Von Arbin
Journal:  J Intern Med       Date:  2001-05       Impact factor: 8.989

2.  A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

Authors:  Karl Claxton; Mark Sculpher; Michael Drummond
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

3.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

Review 4.  Response shift theory: important implications for measuring quality of life in people with disability.

Authors:  Carolyn E Schwartz; Elena M Andresen; Margaret A Nosek; Gloria L Krahn
Journal:  Arch Phys Med Rehabil       Date:  2007-04       Impact factor: 3.966

5.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

6.  Treatment of acquired aphasia: speech therapists and volunteers compared.

Authors:  R David; P Enderby; D Bainton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-11       Impact factor: 10.154

Review 7.  Ageism in stroke rehabilitation studies.

Authors:  Eva Joan Gaynor; Sheena Elizabeth Geoghegan; Desmond O'Neill
Journal:  Age Ageing       Date:  2014-03-18       Impact factor: 10.668

8.  Statistical methods to compare functional outcomes in randomized controlled trials with high mortality.

Authors:  Elizabeth Colantuoni; Daniel O Scharfstein; Chenguang Wang; Mohamed D Hashem; Andrew Leroux; Dale M Needham; Timothy D Girard
Journal:  BMJ       Date:  2018-01-03

9.  Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II-III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial.

Authors:  Abualbishr Alshreef; Allan J Wailoo; Steven R Brown; James P Tiernan; Angus J M Watson; Katie Biggs; Mike Bradburn; Daniel Hind
Journal:  Pharmacoecon Open       Date:  2017-09

10.  Valuing health-related quality of life: An EQ-5D-5L value set for England.

Authors:  Nancy J Devlin; Koonal K Shah; Yan Feng; Brendan Mulhern; Ben van Hout
Journal:  Health Econ       Date:  2017-08-22       Impact factor: 3.046

View more
  6 in total

1.  Telerehabilitation services for stroke.

Authors:  Kate E Laver; Zoe Adey-Wakeling; Maria Crotty; Natasha A Lannin; Stacey George; Catherine Sherrington
Journal:  Cochrane Database Syst Rev       Date:  2020-01-31

2.  A Virtual, Randomized, Control Trial of a Digital Therapeutic for Speech, Language, and Cognitive Intervention in Post-stroke Persons With Aphasia.

Authors:  Michelle Braley; Jordyn Sims Pierce; Sadhvi Saxena; Emily De Oliveira; Laura Taraboanta; Veera Anantha; Shaheen E Lakhan; Swathi Kiran
Journal:  Front Neurol       Date:  2021-02-12       Impact factor: 4.003

3.  Factors Associated With Adherence to Self-Managed Aphasia Therapy Practice on a Computer-A Mixed Methods Study Alongside a Randomized Controlled Trial.

Authors:  Madeleine Harrison; Rebecca Palmer; Cindy Cooper
Journal:  Front Neurol       Date:  2020-11-23       Impact factor: 4.003

4.  Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.

Authors:  Laura Flight; Steven Julious; Alan Brennan; Susan Todd
Journal:  Med Decis Making       Date:  2021-12-03       Impact factor: 2.583

5.  Point-of-care tools to support optometric care provision to people with age-related macular degeneration: A randomised, placebo-controlled trial.

Authors:  Sena A Gocuk; Allison M McKendrick; Laura E Downie
Journal:  Ophthalmic Physiol Opt       Date:  2022-03-14       Impact factor: 3.992

6.  A pilot economic evaluation of a feasibility trial for SUpporting wellbeing through PEeR-Befriending (SUPERB) for post-stroke aphasia.

Authors:  Chris Flood; Nicholas Behn; Jane Marshall; Alan Simpson; Sarah Northcott; Shirley Thomas; Kimberley Goldsmith; Sally McVicker; Mireia Jofre-Bonet; Katerina Hilari
Journal:  Clin Rehabil       Date:  2022-02-02       Impact factor: 3.477

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.